ReviewMayo Clinic proceedings2014
Evaluation and management of patients with heart disease and cancer: cardio-oncology.
Review in Mayo Clinic proceedings, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03694262 (An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma), which is not on this map. Cited by 188 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
Who cites it
188 citing papers in PubMed, 3 syntheses or guidelines pooled it, 416 citations in OpenAlex.
- The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies.Global heart · 2025Pooled it
- Aerobic Exercise and Cardiac Function of Murines Exposed to Doxorubicin: a Meta-Analysis.Arquivos brasileiros de cardiologia · 2020Pooled it
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.Circulation · 2018Pooled it
- Interpretable machine learning for cardiovascular disease risk prediction in cancer survivors: development and internal validation.Cardio-oncology (London, England) · 2026Article
- Evaluating the role of survivorship care plans in modifying disparities in health status among female cancer survivors in Maryland.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Pharmacovigilance assessment of vinorelbine-associated adverse events using FAERS and VigiBase.Medicine · 2026Article
- Cardiovascular risk after cancer in patients with ischemic heart disease or peripheral artery disease.Cardio-oncology (London, England) · 2026Article
- Impact of Pre-Existing Cardiovascular and Metabolic Conditions on the Development of Heart Failure After Paclitaxel Therapy: Real-World Study Based on a Nationwide Claims Database in Japan.Circulation reports · 2026Article
- Analysis of independent prognostic factors for the occurrence and severity of heart failure after chemotherapy in patients with small cell lung cancer.Experimental and therapeutic medicine · 2026Article
- Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications.Frontiers in cardiovascular medicine · 2026Article
- Frailty Meets Cardio-oncology: A New Frontier in Personalised Cancer Care.European cardiology · 2026Review
- Heart failure related cardiotoxicity in breast cancer survivors: a scoping review.Cardio-oncology (London, England) · 2025Review
- PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors.Journal of the American Heart Association · 2025Observational
- Cancer Reversion Therapy: Prospects, Progress and Future Directions.Current issues in molecular biology · 2025Review
- Monitoring high-risk patients for chemotherapy-related cardiotoxicity: A retrospective analysis.World journal of clinical cases · 2025Article
- Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunction.European heart journal open · 2025Article
- Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer.Breast cancer research and treatment · 2025Article
- Longitudinal Patterns of Cardiovascular Disease and Cancer Mortality in Renal Cell Carcinoma Patients by Tumor Stage.JACC. CardioOncology · 2025Article
- Explainable machine learning for neoplasms diagnosis via electrocardiograms: an externally validated study.Cardio-oncology (London, England) · 2025Article
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
128 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The care for patients with cancer has advanced greatly over the past decades. A combination of earlier cancer diagnosis and greater use of traditional and new systemic treatments has decreased cancer-related mortality. Effective cancer therapies, however, can result in short- and long-term comorbidities that can decrease the net clinical gain by affecting quality of life and survival. In particular, cardiovascular complications of cancer treatments can have a profound effect on the health of patients with cancer and are more common among those with recognized or unrecognized underlying cardiovascular diseases. A new discipline termed cardio-oncology has thus evolved to address the cardiovascular needs of patients with cancer and optimize their care in a multidisciplinary approach. This review provides a brief introduction and background on this emerging field and then focuses on its practical aspects including cardiovascular risk assessment and prevention before cancer treatment, cardiovascular surveillance and therapy during cancer treatment, and cardiovascular monitoring and management after cancer therapy. The content of this review is based on a literature search of PubMed between January 1, 1960, and February 1, 2014, using the search terms cancer, cardiomyopathy, cardiotoxicity, cardio-oncology, chemotherapy, heart failure, and radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.